AU2022273863A1 - Recombinant tert-encoding viral genomes and vectors - Google Patents

Recombinant tert-encoding viral genomes and vectors Download PDF

Info

Publication number
AU2022273863A1
AU2022273863A1 AU2022273863A AU2022273863A AU2022273863A1 AU 2022273863 A1 AU2022273863 A1 AU 2022273863A1 AU 2022273863 A AU2022273863 A AU 2022273863A AU 2022273863 A AU2022273863 A AU 2022273863A AU 2022273863 A1 AU2022273863 A1 AU 2022273863A1
Authority
AU
Australia
Prior art keywords
aav9
aav
promoter
spb
cmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022273863A
Other languages
English (en)
Inventor
María Blasco
Maria Fàtima BOSCH TUBERT
Estefanía CASANA LORENTE
Miquel Garcia Martinez
Verónica JIMENEZ CENZANO
Paula MARTINEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telomere Therapeutics Sl
Universitat Autonòma de Barcelona
Fundacion del Sector Publico Estatal Centro Nacional de Investigaciones Oncologicas Carlos III FSP CNIO
Original Assignee
Telomere Therapeutics Sl
Universitat Autonòma de Barcelona
Fundacion del Sector Publico Estatal Centro Nacional de Investigaciones Oncologicas Carlos III FSP CNIO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telomere Therapeutics Sl, Universitat Autonòma de Barcelona, Fundacion del Sector Publico Estatal Centro Nacional de Investigaciones Oncologicas Carlos III FSP CNIO filed Critical Telomere Therapeutics Sl
Publication of AU2022273863A1 publication Critical patent/AU2022273863A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022273863A 2021-05-12 2022-05-12 Recombinant tert-encoding viral genomes and vectors Pending AU2022273863A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382441.0A EP4089171A1 (en) 2021-05-12 2021-05-12 Recombinant tert-encoding viral genomes and vectors
EP21382441.0 2021-05-12
PCT/EP2022/062990 WO2022238557A1 (en) 2021-05-12 2022-05-12 Recombinant tert-encoding viral genomes and vectors

Publications (1)

Publication Number Publication Date
AU2022273863A1 true AU2022273863A1 (en) 2023-12-07

Family

ID=75919286

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022273863A Pending AU2022273863A1 (en) 2021-05-12 2022-05-12 Recombinant tert-encoding viral genomes and vectors

Country Status (9)

Country Link
US (2) US20250099618A1 (cg-RX-API-DMAC7.html)
EP (2) EP4089171A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024521063A (cg-RX-API-DMAC7.html)
CN (1) CN117836420A (cg-RX-API-DMAC7.html)
AU (1) AU2022273863A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219795A1 (cg-RX-API-DMAC7.html)
ES (1) ES3073712T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023013385A (cg-RX-API-DMAC7.html)
WO (1) WO2022238557A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12668817B1 (en) * 2025-07-10 2026-06-30 Telomere Therapeutics S.L. Recombinant adeno-associated viral vectors for delivering a therapeutic gene to lungs

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
CA2188157A1 (en) * 1994-05-18 1995-11-23 Children's Hospital Medical Center Nucleic acid sequences controlling lung cell-specific gene expression
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
EP1007637B1 (en) 1997-04-14 2004-06-30 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
CN1247788C (zh) 1997-05-13 2006-03-29 北卡罗来纳-查佩尔山大学 基于慢病毒的基因转移载体
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
DE19909769A1 (de) 1999-03-05 2000-09-07 Bundesrepublik Deutschland Let Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
US20080188431A1 (en) * 2004-09-08 2008-08-07 Chiorini John A Transcytosis of Adeno-Associated Viruses
ES2590461T3 (es) * 2010-07-02 2016-11-22 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii La transcriptasa inversa de la telomerasa como protección frente al envejecimiento
US9453209B2 (en) * 2012-12-27 2016-09-27 Sierra Sciences, Llc Enhancing health in mammals using telomerase reverse transcriptase gene therapy
ES2936383T3 (es) 2014-08-08 2023-03-16 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio Terapias basadas en transcriptasa inversa de la telomerasa para el tratamiento de afecciones asociadas con el infarto de miocardio
EP3485914B1 (en) 2014-08-08 2021-01-13 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Telomerase reverse transcriptase-based therapies

Also Published As

Publication number Publication date
US20260115322A1 (en) 2026-04-30
WO2022238557A1 (en) 2022-11-17
ES3073712T3 (en) 2026-07-14
EP4337780A1 (en) 2024-03-20
MX2023013385A (es) 2024-02-06
US20250099618A1 (en) 2025-03-27
EP4337780B1 (en) 2026-04-01
CN117836420A (zh) 2024-04-05
EP4089171A1 (en) 2022-11-16
JP2024521063A (ja) 2024-05-28
EP4337780C0 (en) 2026-04-01
CA3219795A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
EP3684423B1 (en) Adeno-associated virus variant capsids and methods of use thereof
US20240084334A1 (en) Serpina-modulating compositions and methods
US11999965B2 (en) Bocaparvovirus small noncoding RNA and uses thereof
CN113853207A (zh) 新型aav衣壳和含有其的组合物
EP3236984B1 (en) Adeno-associated virus vectors encoding modified g6pc and uses thereof
TW202033224A (zh) 藉靶向肌營養相關蛋白基因治療肌肉萎縮症之方法
CN113508130A (zh) 用于治疗达农病的基因治疗载体
US20260055144A1 (en) Recombinant adeno-associated viruses and uses thereof
WO2021113634A1 (en) Transgene cassettes designed to express a human mecp2 gene
WO2023237748A1 (en) Peptide-modified aav capsid with enhanced muscle transduction efficiency
CN113755524A (zh) 用于治疗脊髓性肌萎缩的腺相关病毒载体及其用途
CN115885040A (zh) 可用于治疗cdkl5缺乏症(cdd)的组合物
JP2025534666A (ja) 操作された核酸調節エレメントならびにその使用方法
US20260115322A1 (en) Recombinant tert-encoding viral genomes and vectors
WO2023035687A1 (zh) 用于治疗庞贝氏病的基因治疗构建体、药物组合物和方法
CN115605501A (zh) 肌肉特异性核酸调节元件及其方法和用途
CN112041437A (zh) 用于恢复f8基因功能的腺相关病毒组合物和其使用方法
CA3218631A1 (en) Vector system
KR20230082613A (ko) Cns 또는 근육 전달을 위한 재조합 아데노-연관 바이러스
CN115820740A (zh) 用于治疗ⅱ型粘多糖贮积症的重组腺相关病毒载体及其应用
EP4665749A1 (en) Nucleic acids encoding bcl2-associated athanogene 3 (bag3) for gene therapy
HK40109651A (en) Recombinant tert-encoding viral genomes and vectors
WO2025023319A1 (ja) 脳指向性aav変異体
WO2020187272A1 (zh) 一种用于基因治疗的融合蛋白及其应用
HK40036161A (zh) 腺相关病毒变异衣壳和其使用方法